Ichinosuke Hyodo

Ichinosuke Hyodo

Auto-generated profile, based on publicly available information

Ichinosuke Hyodo

Department of Gastrointestinal Medical Oncology, NHO Shikoku Cancer Center, Matsuyama, Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2010 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
IHIchinosuke Hyodo
Ichinosuke Hyodo
HSHideo Suzuki
Hideo Suzuki
KTKeiichi Takahashi
Keiichi Takahashi
YSYoko Saito
Yoko Saito
STShinji Tanaka
Shinji Tanaka
NBNarikazu Boku
Narikazu Boku
To reveal the present status and future directions of colorectal cancer in Asia. The Working Group consisted of oncologists from six Asian countries (Japan, Korea, Hong Kong, China, Taiwan, Singapore and Philippines) discussed colorectal cancer in the 30th Asia-Pacific Cancer Conference and made a consensus report. The incidence of colorectal cancer has been increasing rapidly in recent decades, and mortality has also increased except in Japan and Singapore. Colorectal screening with fecal occult blood tests is a national policy in Taiwan, Japan and Korea. Total colonoscopy is the most common examination for diagnosing colorectal cancers and neoplasms. However, there are differences in the macroscopic classification used. Laparoscopic surgery for colon cancer is extensively used, although the indication varies. Adequate lymph node harvesting of more than 12 nodes is performed in most countries. Neoadjuvant chemoradiation therapy is not routinely done for T2 or T3 rectal cancer. Total mesorectal excision is the standard surgery for rectal cancer. Survival rate data are unavailable for many countries and should be compiled in all. The differences in the health-care delivery systems affect the treatment choices for unresectable colorectal cancer. Infusional 5-FU plus leucovorin plus oxaliplatin (FOLFOX) is the most popular first-line regimen. Cetuximab is mainly used as a second- or third-line regimen with reference to k-ras mutation. Oxaliplatin-based adjuvant chemotherapy is commonly used for stage III disease, whereas the clinical practice for stage II disease varies. Further clinical cooperation is needed to optimize the management of colorectal cancer in Asia.

7 December 2010 in Cancer Science
Verified
Journal Article
Open access
PDF file
SEShinji Endo
Shinji Endo
KYKenji Yamato
Kenji Yamato
SHSachiko Hirai
Sachiko Hirai
TMToshikazu Moriwaki
Toshikazu Moriwaki
KFKuniaki Fukuda
Kuniaki Fukuda
IHIchinosuke Hyodo
Ichinosuke Hyodo
The tumor suppressor gene p53 is the most frequently mutated gene in human cancers. However, its mutation rate is relatively low in gastric cancer compared with other cancers. In this study, we investigated the mechanisms underlying the antitumor effects of nutlin‐3, an inhibitor of human homolog of murine double minute 2 (MDM2). MDM2 is a negative regulator of p53. Four gastric cancer cell lines with wild‐type p53 (wt p53) and three with mutant‐type p53 (mt p53) were analyzed for MDM2 and MDM4 expression by immunoblotting, and for their gene amplification by quantitative real‐time PCR. Moreover, the viability of cells exposed to nutlin‐3 was examined by WST‐8 assay, and the expression of p53 and its downstream genes was analyzed by immunoblotting. Nutlin‐3 stabilized p53 and increased the expression of p21WAF1 and Noxa, and cleaved poly (ADP)‐ribose polymerase regardless of the pre‐expression levels of MDM2 and MDM4 in gastric cancer cells with wt p53. Flow cytometry revealed that nutlin‐3 arrested the cell cycle in G1 phase and induced apoptosis in the cell lines. These nutlin‐3 effects were not observed in the cell lines with mt p53. Nutlin‐3 exerted additive or synergistic cytotoxicity in combination with 5‐fluorouracil or cisplatin in most cell lines with wt p53. An in vivo antitumor effect of nutlin‐3 alone and its additive augmentation by 5‐fluorouracil were confirmed in an MDM2 overexpressed xenograft tumor model. Nutlin‐3 showed potent antitumor activity against human gastric cancer cells with wt p53 and shows promise as a single agent and in combination with conventional anticancer drugs. (Cancer Sci 2011; 102: 605–613)

21 April 2010 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
THTakayuki Hisanaga
Takayuki Hisanaga
TSTakuya Shinjo
Takuya Shinjo
TMTatsuya Morita
Tatsuya Morita
NNNobuhisa Nakajima
Nobuhisa Nakajima
MIMasayuki Ikenaga
Masayuki Ikenaga
IHIchinosuke Hyodo
Ichinosuke Hyodo
The aim of this study was to evaluate the efficacy and safety of octreotide for malignant bowel obstruction in a multicenter study. Terminally ill patients diagnosed with inoperable malignant bowel obstruction were treated with octreotide 300 µg/day. The primary endpoint was the overall improvement rate of subjective abdominal symptoms. The degrees of nausea, vomiting, abdominal pain, distension, anorexia, fatigue, thirst and overall quality of life were evaluated by the self-rating scores selected from the MD Anderson Symptoms Inventory and Kurihara's Face Scale. Forty-nine patients were enrolled in the study, and 46 patients received study treatment, including 17 gastric, 13 colorectal, 7 ovarian and other cancers. The median survival time was 25 days. The number of vomiting episodes significantly correlated with the MD Anderson Symptoms Inventory nausea and vomiting scores (P< 0.001) before octreotide treatment. Of 43 patients evaluable for efficacy, the scores of all the MD Anderson Symptoms Inventory items except abdominal pain and the number of vomiting episodes improved during the first 4 days of octreotide treatment (P< 0.0062). The MD Anderson Symptoms Inventory scores were decreased in 59–72% of patients, and overall quality-of-life scores improved in 56% of patients. No serious adverse events were observed. The high improvement rate in abdominal symptoms suggested the efficacy of octreotide in terminally ill patients with malignant bowel obstruction.

1 June 2004 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
TYTakekazu Yamao
Takekazu Yamao
YSYasuhiro Shimada
Yasuhiro Shimada
KSKuniaki Shirao
Kuniaki Shirao
AOAtsushi Ohtsu
Atsushi Ohtsu
NINobumasa Ikeda
Nobumasa Ikeda
SYShigeaki Yoshida
Shigeaki Yoshida
Background: The efficacy of systemic chemotherapy against peritoneal dissemination from advanced gastric cancer (AGC) remains unclear, because the peritoneal dissemination was not defined as a measurable lesion in conventional phase II studies. In this study, we evaluated the efficacy and toxicity of sequential MTX and 5FU therapy (MF) in chemotherapy-naive patients with AGC accompanied by malignant ascites in a phase II setting. Methods: The treatment schedule comprised weekly administration of MTX (100 mg/m2, i.v. bolus) followed by 5FU (600 mg/m2, i.v. bolus) with a 3 h interval. Leucovorin rescue (10 mg/m2 every 6 h, for a total of six times) was commenced 24 h after MTX administration. Results: Thirty-seven chemotherapy-naive patients with AGC presenting with malignant ascites were enrolled in this trial. The median age was 60 years (range, 25–74 years) and most patients (86%) had a performance status of 0–1. In total, 355 administrations of the sequential MTX/5FU therapy were performed. Major toxicity consisted of myelosuppression and gastrointestinal toxicity. Grade 4 neutropenia occurred in 10.8% of the patients. The overall objective response rate was 5.7% (two partial responses in 35 patients; 95% confidence interval: 0.7–19.2%). However, the response rate of ascites was 35.1% (complete disappearance in three patients and apparent decrease in 10 patients; 95% confidence interval: 20.2–52.5%). Conclusions: Sequential MTX/5FU therapy is effective against AGC with malignant ascites with acceptable toxicity and warrants further investigations in a phase III setting.

18 January 2010 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
IHIchinosuke Hyodo
Ichinosuke Hyodo
TMTatsuya Morita
Tatsuya Morita
IAIsamu Adachi
Isamu Adachi
YSYasuo Shima
Yasuo Shima
AYAkitaka Yoshizawa
Akitaka Yoshizawa
KHKazuaki Hiraga
Kazuaki Hiraga
Objective To develop a predicting tool for survival of terminally ill cancer patients. Methods This prospective, multicenter study was composed of two cohorts of samples: development and test. In the development sample of terminally ill cancer patients, 32 candidate predictors were studied to develop a new tool, Japan Palliative Oncology Study-Prognostic Index using the Cox proportional hazard model. Then the test sample was studied to validate Japan Palliative Oncology Study-Prognostic Index and compared it with the conventional predicting tools, such as palliative prognostic score and simplified palliative prognostic index. Results Five significant predictors, physician's clinical prediction of survival, consciousness, pleural effusion, white blood cell count and lymphocyte % were derived from the analysis of 201 patients, and Japan Palliative Oncology Study-Prognostic Index was developed using these predictors. It could divide patients into three risk groups: low (A), intermediate (B) and high (C). Median survival times for Groups A, B and C were 51, 35 and 16 days, respectively. Survival probability for more than 30 days for Groups A, B and C in the development sample was 78%, 61% and 16%, respectively. Japan Palliative Oncology Study-Prognostic Index was studied in subsequent 208 patients for the test sample, and constant results (median survival times for Groups A, B and C; 67, 31 and 10 days, and survival probability for more than 30 days for Groups A, B and C; 81, 48 and 11%) were obtained. Palliative prognostic score can also predict three risk groups well, but simplified palliative prognostic index could not discriminate low risk from intermediate risk group. Conclusion Japan Palliative Oncology Study-Prognostic Index, a tool to predict survival, has been developed. Its reliability should be confirmed further in the future study, comparing with palliative prognostic score.

23 October 2016 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
SSSatoshi Shiono
Satoshi Shiono
TOTakehiro Okumura
Takehiro Okumura
NBNarikazu Boku
Narikazu Boku
THTomoyuki Hishida
Tomoyuki Hishida
YOYasuhisa Ohde
Yasuhisa Ohde
HKHaruhiko Kondo
Haruhiko Kondo
OBJECTIVES: Although wedge resection is the most common surgical procedure for pulmonary metastases from colorectal cancer, there are few reports about segmentectomy for colorectal metastasectomy.